
What is claimed is:

1. A compound of the general Formula I



I

and stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein:

X^1 is N or CR^{3a} and X^2 is N or CR^{3b};

R^{3a} and R^{3b} are independently H, (1-6C alkyl), CF_3, F, Cl, CN, or (3-6C)cycloalkyl;

R^1 is $hetAr^1$, $hetAr^2$, $hetAr^3$, Ar^1, Ar^2, $C(=O)NR^aR^b$, (3-6C)cycloalkyl, or N-(1-3C alkyl)pyridinonyl;

$hetAr^1$ is a 5 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more substituents independently selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, (1-4C alkoxy)(1-6C)alkyl, trimethylsilyl(1-4C alkoxy)(1-6C)alkyl, (3-6C)cycloalkyl, a 4-6 membered oxacyclic ring, $hetCyc^a$(1-2C)alkyl, $hetAr^a$(1-2C)alkyl and (1-4C alkylsulfonyl)(1-6C alkyl);

$hetCyc^a$ is a 6 membered heterocycle having 1-2 ring heteroatoms independently selected from N and O and is optionally substituted with (1-6C)alkyl;

$hetAr^a$ is a 6 membered heteroaryl having 1-2 ring nitrogen atoms;

$hetAr^2$ is a 9-membered bicyclic partially unsaturated or fully unsaturated heterocyclic ring having 3 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

$hetAr^3$ is a 6 membered heteroaryl having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl, $hetCyc^b$ and (1-6C)alkoxy;

$hetCyc^b$ is a 6-membered heterocycle having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

Ar^1 is phenyl substituted with a substituent selected from $hetCyc^c$, $hetCyc^d$, $hetAr^b$, trifluoro(1-6C)alkyl and (1-6C)alkoxy;

$hetCyc^c$ is a 6 membered heterocycle having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

$hetCyc^d$ is an 8-membered bridged heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O;

$hetAr^b$ is a 5-membered heteroaryl ring having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

Ar^2 is a benzo ring fused to a 5-6 membered azacyclic ring and is optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

R^a is H;

R^b is (1-6C)alkyl, (3-6C)cycloalkyl or $hetAr^c$;

$hetAr^c$ is a 6-membered heteroaryl having 1-2 ring N atoms;

R^2 is hydrogen, halogen, (1-4C)alkyl, CF_3, CN, (3-4C)cycloalkyl, azetidinyl or oxetanyl;

R^3 is hydrogen, (1-6C)alkyl, CF_3, F, Cl, CN or (3-6C)cycloalkyl;

R^4 is H or (1-6C)alkyl, and

R^5 is H, (1-6C)alkyl, $-CH_2CN$, (3-6C)cycloalkyl (optionally substituted by one or more halogens), $hetCyc^e$, Ar^a or $hetAr^d$,

or R^4 and R^5 together with the carbon atom to which they are attached form a 4-6 membered azacyclic ring optionally substituted with a substituent selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, benzyl, $-CH_2$(3-6C cycloalkyl), $-CH_2hetCyc^f$, -C(=O)O(1-6Calkyl), -C(=O)(1-6Calkyl), $-C(=O)(CR'R'')CF_3$, $hetAr^e$, (3-6C)cycloalkyl, a 4-6 membered oxacyclic ring and $-SO_2R^c$,

or R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered oxacyclic ring,

or R^4 and R^5 together with the carbon atom to which they are attached form a 3-6 membered carbocyclic ring optionally substituted with (1-6C)alkyl,

or R^4 and R^5 together with the carbon atom to which they are attached form a 7-9 membered bicyclic spiro carbocycle,

or R^4 and R^5 together with the carbon atom to which they are attached form a 7-9 membered bicyclic spiro heterocycle having a ring heteroatom selected from O and N, wherein said ring nitrogen atom when present is optionally substituted with a substituent selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl and $-SO_2R^c$;

$hetCyc^e$ is a 5-6-membered heterocycle having a ring N atom and substituted with a substituents selected from C(=O)(1-6C)alkyl;

Ar^a is phenyl optionally substituted with one or more substituents independently selected from halogen, CF_3, (1-6C)alkyl and (1-6C)alkoxy;

$hetAr^d$ is a 6-membered heteroaryl having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from halogen, (1-6C)alkoxy, (1-6C)alkyl and CF_3;

$hetCyc^f$ is a 6-membered oxacyclic ring;

R' and R" are independently hydrogen or methyl, or

R' and R" together with the carbon atom to which they are attached form a cyclopropylidine ring;

$hetAr^e$ is a 6-membered heteroaryl ring having 1-2 ring nitrogen atoms;

R^c is (1-6C)alkyl, fluoro(1-3C)alkyl, difluoro(1-3C)alkyl trifluoro(1-3C)alkyl, tetrafluoro(1-3C)alkyl, pentafluro(1-3C)alkyl, (3-6C)cycloalkyl (optionally substituted with (1-6C)alkyl), or phenyl (optionally substituted with one or more groups independently selected from (1-6C alkyl), CF_3, CF_3O- and halogen);

R^6 is hydrogen or methyl; and

R^7 is hydrogen or (1-6C)alkyl.

2. The compound of claim 1, wherein:

X^1 is N or CR^{3a} and X^2 is N or CR^{3b}, wherein only one of X^1 and X^2 may be N;

R^{3a} and R^{3b} are independently H, (1-6C alkyl) or CF_3;

R^1 is $hetAr^1$, $hetAr^2$, $hetAr^3$, Ar^1, Ar^2 or $C(=O)NR^aR^b$;

$hetAr^1$ is a 5 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more substituents independently selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, (1-4C alkoxy)(1-6C)alkyl, trimethylsilyl(1-4C alkoxy)(1-6C)alkyl, (3-6C)cycloalkyl, a 4-6 membered oxacyclic ring, $hetCyc^a$(1-2C)alkyl and $hetAr^a$(1-2C)alkyl;

hetCyc^a is a 6 membered heterocycle having 1-2 ring heteroatoms independently selected from N and O and is optionally substituted with (1-6C)alkyl;

hetAr^a is a 6 membered heteroaryl having 1-2 ring nitrogen atoms;

hetAr^2 is a 9-membered bicyclic partially unsaturated or fully unsaturated heterocyclic ring having 3 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

hetAr^3 is a 6 membered heteroaryl having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl and hetCyc^b;

hetCyc^b is a 6-membered heterocycle having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

Ar^1 is phenyl substituted with a substituent selected from hetCyc^c, hetCyc^d and hetAr^b; hetCyc^c is a 6 membered heterocycle having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

hetCyc^d is an 8-membered bridged heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O;

hetAr^b is a 5-membered heteroaryl ring having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

Ar^2 is a benzo ring fused to a 5-6 membered azacyclic ring and is optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

R^a is H;

R^b is (1-6C)alkyl, (3-6C)cycloalkyl or hetAr^c;

hetAr^c is a 6-membered heteroaryl having 1-2 ring N atoms;

R^2 is hydrogen, F, Cl or CN;

R^3 is hydrogen or (1-6C)alkyl;

R^4 is H or (1-6C)alkyl, and

R^5 is H, (1-6C)alkyl, -CH_2CN, (3-6C)cycloalkyl, hetCyc^e, Ar^a or hetAr^d,

or R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered azacyclic ring optionally substituted with a substituent selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, benzyl, -CH_2(3-6C

cycloalkyl), -CH_2hetCyc^f, -C(=O)O(1-6Calkyl), -C(=O)(1-6Calkyl), -C(=O)(CR'R")CF_3, hetAr^e, (3-6C)cycloalkyl, a 4-6 membered oxacyclic ring and -SO_2R^c,

or R^4 and R^5 together with the carbon atom to which they are attached form a 6-membered azacyclic ring substituted with a substituent selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, benzyl, -CH_2((3-6C cycloalkyl), -CH_2hetCyc^f, -C(=O)O(1-6Calkyl), -C(=O)(1-6Calkyl), -C(=O)(CR'R")CF_3, hetAr^e, (3-6C)cycloalkyl, a 4-6 membered oxacyclic ring and -SO_2R^c,

or R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered oxacyclic ring,

or R^4 and R^5 together with the carbon atom to which they are attached form a 3-6 membered carbocyclic ring;

hetCyc^e is a 5-6-membered heterocycle having a ring N atom and substituted with a substituents selected from C(=O)(1-6C)alkyl;

Ar^a is phenyl optionally substituted with one or more substituents independently selected from halogen, CF_3, (1-6C)alkyl and (1-6C)alkoxy;

hetAr^d is a 6-membered heteroaryl having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from halogen, (1-6C)alkoxy, (1-6C)alkyl and CF_3;

hetCyc^f is a 6-membered oxacyclic ring;

R' and R" are independently hydrogen or methyl, or

R' and R" together with the carbon atom to which they are attached form a cyclopropylidine ring;

hetAr^e is a 6-membered heteroaryl ring having 1-2 ring nitrogen atoms;

R^c is (1-6C)alkyl, fluoro(1-3C)alkyl, difluoro(1-3C)alkyl trifluoro(1-3C)alkyl, tetrafluoro(1-3C)alkyl, pentafluro(1-3C)alkyl, (3-6C)cycloalkyl or phenyl;

R^6 is hydrogen; and

R^7 is hydrogen or (1-6C)alkyl.

2. A compound according to claim 1, wherein R^1 is hetAr^1 or hetAr^2.

3. A compound according to claim 1 or 2, wherein R^1 is hetAr^1.

4. A compound according to any of claims 1-3, wherein hetAr^1 is pyrazolyl, thiazolyl, oxazolyl, thiadiazolyl, imidazolyl, pyrrolyl or thiophenyl optionally substituted with one or more substituents independently selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, (1-4C alkoxy)(1-6C)alkyl,

trimethylsilyl(1-4C alkoxy)(1-6C)alkyl, (3-6C)cycloalkyl, a 4-6 membered oxacyclic ring, hetCyc^a(1-2C)alkyl and hetAr^a(1-2C)alkyl.

5. A compound according to any of claims 1-4, wherein hetAr^1 is pyrazol-4-yl, thiazol-5-yl, imidazol-1-yl or 1,3,4-thiadiazol-2-yl optionally substituted with one or more substituents independently selected from methyl, ethyl, isopropyl, isobutyl, 2,2,2-trifluoroethyl, (2-isopropoxy)ethyl, trimethylsilylethoxymethyl, cyclobutyl, oxetanyl, 4-tetrahydro-2H-pyranyl, (4-methylpiperazinyl)ethyl and pyrid-3-ylmethyl.

6. A compound according to any of claims 1-5, wherein hetAr^1 is pyrazol-4-yl optionally substituted with a substituent selected from methyl, ethyl, isopropyl, isobutyl, 2,2,2-trifluoroethyl, (2-isopropoxy)ethyl, trimethylsilylethoxymethyl, cyclobutyl, oxetanyl, 4-tetrahydro-2H-pyranyl, (4-methylpiperazinyl)ethyl and pyrid-3-ylmethyl.

7. A compound according to claim 1 or 2, wherein R^1 is hetAr^2.

8. A compound according to any of claims 1, 2 or 7, wherein hetAr^2 is 5,6,7,8-tetrahydroimidazo[1,2-a]pyrazinyl optionally substituted with one or more substituents independently selected from (1-6C)alkyl.

9. A compound according to claim 1 or 2, wherein R^1 is hetAr^3.

10. A compound according to any of claims 1, 2, or 9, wherein hetAr^3 is pyridyl or pyrimidyl optionally substituted with one or more substituents independently selected from (1-6C)alkyl or hetCyc^b.

11. A compound according to any of claims 1, 2, 9 or 10, wherein R^1 is pyridyl optionally substituted with methyl or 4-methylpiperizinyl.

12. A compound according to claim 1, wherein R^1 is selected from Ar^1 and Ar^2.

13. A compound according to claim 1 or 12, wherein R^1 is Ar^1.

14. A compound according to any of claims 1, 12 or 13, wherein Ar^1 is phenyl optionally substituted with a substituent selected from (i) morpholinyl, (ii) piperidinyl optionally substituted with (1-6C)alkyl, (iii) piperazinyl optionally substituted with (1-6C)alkyl, (iv) oxa-3-azabicyclo[3.2.1]octane, and (v) pyrazolyl optionally substituted with (1-6C)alkyl.

15. A compound according to any of claims 1, 13 or 14, wherein Ar^1 is phenyl substituted with a substituent selected from morpholin-4-yl, 1-methylpiperidin-4-yl, 1-methylpiperizin-4-yl, 8-oxa-3-azabicyclo[3.2.1]octanyl and 1-methyl-1H-pyrazolyl.

16. A compound according to claim 1 or 12, wherein R^1 is Ar^2.

17. A compound according to any of claims 1, 12 or 16, wherein Ar^2 is 1,2,3,4-tetrahydroisoquinolin-6-yl or 1,2,3,4-tetrahydroisoquinolin-7-yl optionally substituted with one or more substituents independently selected from (1-6C)alkyl.

18. A compound according to any of claims 1, 12, 16 or 17, wherein Ar^2 is 1,2,3,4-tetrahydroisoquinolin-6-yl, 2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl, 1,2,3,4-tetrahydroisoquinolin-7-yl or 2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl.

19. A compound according to claim 1, wherein R^1 is $C(=O)NR^aR^b$.

20. A compound according to any of claims 1-19, wherein R^4 is H or (1-6C)alkyl, and R^5 is H, (1-6C)alkyl, $-CH_2CN$, (3-6C)cycloalkyl, $hetCyc^e$, Ar^a or $hetAr^d$.

21. A compound according to any of claims 1-20, wherein R^4 is H or (1-6C)alkyl, and R^5 is H, methyl, t-butyl, 2,2-dimethylpropyl, cyanomethyl, cyclopropyl, cyclobutyl, cyclopentyl, 1-acetylpiperidin-4-yl, phenyl, trifluoromethylphenyl, chlorophenyl, pyridyl, methoxypyridyl or bromopyridyl.

22. A compound according to any of claims 1-21, wherein R^4 is H or (1-6C)alkyl, and R^5 is cyclopropyl, cyclobutyl or cyclopentyl.

23. A compound according to any of claims 1-22, wherein R^4 is H.

24. A compound according to any of claims 1-19, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered azacyclic ring optionally substituted with a substituent selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, benzyl, $-CH_2$(3-6C cycloalkyl), $-CH_2hetCyc^f$, $-C(=O)O$(1-6Calkyl), $-C(=O)$(1-6Calkyl), $-C(=O)(CR'R'')CF_3$, $hetAr^e$, (3-6C)cycloalkyl, a 4-6 membered oxacyclic ring and $-SO_2R^e$.

25. A compound according to any of claims 1-19 or 24, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered azacyclic ring optionally substituted with a substituent selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, $-CH_2$(3-6C cycloalkyl), $-CH_2hetCyc^f$, (3-6C)cycloalkyl and $-SO_2R^e$.

26. A compound according to any of claims 1-19, 24, or 25, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered azacyclic ring optionally substituted with a substituent selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl and pentafluoro(1-6C)alkyl.

27. A compound according to any of claims 1-19, 24, 25 or 26, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered azacyclic ring optionally substituted with a substituent selected from methyl, ethyl, propyl, isopropyl, isobutyl, fluoromethyl, 3-fluoropropyl, 2-fluoroethyl, 2,2-difluoroethyl, 2,2,3,3-tetrafluoropropyl,, 1,3-difluoroprop-2-yl, 2,2,2-trifluoroethyl, 3,3,3-trifluoropropyl, and 2,2,3,3,3-pentafluoropropyl.

28. A compound according to any of claims 1-19 or 24, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered azacyclic ring substituted with -C(=O)O(1-6Calkyl), -C(=O)(1-6Calkyl), -C(=O)(CR'R")CF_3.

29. A compound according to any of claims 1-19 or 24, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered azacyclic ring substituted with $hetAr^e$.

30. A compound according to any of claims 1-19, 24 or 29, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered azacyclic ring substituted with pyrimidin-2-yl.

31. A compound according to any of claims 1-19, 24 or 25, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered azacyclic ring substituted with $-SO_2R^c$.

32. A compound according to any of claims 1-19, 24, 25 or 31, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered azacyclic ring substituted with $-SO_2CH_3$, $-SO_2CH_2CH_3$, $-SO_2CH_2CH_2CH_3$, $-SO_2CH(CH_3)_2$, $-SO_2CH_2CH_2CF_3$, $-SO_2CF_3$, $-SO_2CF_2CF_3$, -SO_2-cyclopropyl, -SO_2-cyclohexyl or -SO_2-phenyl.

33. A compound according to any of claims 1-19, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 6-membered azacyclic ring substituted with a substituent selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, benzyl, $-CH_2$(3-6C cycloalkyl), $-CH_2hetCyc^f$, -C(=O)O(1-6Calkyl), -C(=O)(1-6Calkyl), -C(=O)(CR'R")CF_3, $hetAr^e$, (3-6C)cycloalkyl, a 4-6 membered oxacyclic ring and $-SO_2R^c$.

34. A compound according to any of claims 1-19 or 33, wherein R^4 and R^5 together with the carbon atom to which they are attached form a piperizin-4-yl ring substituted with (1-6C)alkyl, trifluoro(1-6C)alkyl or -C(=O)O(1-6C alkyl).

35. A compound of claim 1, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 5 membered azacyclic ring optionally substituted with a substituent selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, benzyl, $-CH_2$(3-6C cycloalkyl), $-CH_2$hetCyc^f, -C(=O)O(1-6Calkyl), -C(=O)(1-6Calkyl), $-C(=O)(CR'R'')CF_3$, hetAr^e, (3-6C)cycloalkyl, a 4-6 membered oxacyclic ring and $-SO_2R^c$.

36. A compound according to any of claims 1-19, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered oxacyclic ring.

37. A compound according to any of claims 1-19, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 3-6 membered carbocyclic ring.

38. A compound of claim 1, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 7-9 membered bicyclic spiro carbocycle, or R^4 and R^5 together with the carbon atom to which they are attached form a 7-9 membered bicyclic spiro heterocycle having a ring heteroatom selected from O and N, wherein said ring nitrogen atom when present is optionally substituted with a substituent selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl and $-SO_2R^c$.

38. A compound according to any of claims 1-37, wherein R^7 is hydrogen.

39. A compound according to any of claims 1-37, wherein R^7 is (1-6C)alkyl.

40. A compound according to any of claims 1-39, wherein R^2 is H.

41. A compound according to any of claims 1-39, wherein R^2 is Cl.

42. A compound according to any of claims 1-39, wherein R^2 is CN.

43. A compound according to any of claims 1-42, wherein R^3 is hydrogen.

44. A compound according to any of claims 1-42, wherein R^3 is (1-6C)alkyl.

45. A compound according to any of claims 1-44, wherein X^1 is N and X^2 is CR^{3b}.

46. A compound according to any of claims 1-44, wherein X^1 is CR^{3a} and X^2 is N.

47. A compound according to any of claims 1-44, wherein X^1 is CR^{3a} and X^2 is CR^{3b}.

48. A compound according to any of claims 1-44, 46 or 47 wherein R^{3a} is H.

49. A compound according to any of claims 1-44, 46 or 47 wherein R^{3a} is (1-6C)alkyl.

50. A compound according to any of claims 1-45 or 47 wherein R^{3b} is H.

51. A compound according to any of claims 1-45 or 47 wherein R^{3b} is (1-6C)alkyl.

52. A pharmaceutical composition, which comprises a compound of Formula **I** as defined in any one of claims 1-51 or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable diluent or carrier.

53. A method for treating an autoimmune disease or inflammatory disease in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula **I** as defined in any one of claims 1 to 51 or a pharmaceutically acceptable salt or solvate thereof.


54. A method for treating organ, tissue or cell transplant rejection in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula **I** as defined in any one of claims 1 to 51 or a pharmaceutically acceptable salt or solvate thereof.

55. A method for treating a malignancy in a mammal, which comprises administering to said mammal a therapeutically effective amount of a compound of Formula **I** as defined in any one of claims 1 to 51 or a pharmaceutically acceptable salt or solvate thereof.

56. A compound of Formula **I** as defined in any one of claims 1 to 51 or a pharmaceutically acceptable salt or solvate thereof, for use in therapy.


57. A process for the preparation of a compound of claim 1, which comprises:

(a) coupling a corresponding compound having the formula **II** or a protected derivative thereof



II


where L^1 is a leaving atom and R^1 and R^2 are as defined for Formula **I**, with a corresponding compound having the formula **III**:



III

where R^3, R^4, R^5, R^6, R^7, X^1 and X^2 are as defined for Formula **I** and R^x and R^y are H or (1-6C)alkyl, or R^x and R^y together with the atoms to which they are connected form a 5-6 membered ring optionally substituted with 1-4 substituents selected from (1-3C alkyl), wherein said coupling takes place in the presence of a palladium catalyst and base and optionally in the presence of a ligand; or


(b) for compounds of Formula **I** wherein R^2 is hydrogen, cyclizing a corresponding compound having the formula **IV** or a protected derivative thereof



IV


where R^1, R^3, R^4, R^5, R^6, R^7, X^1 and X^2 are as defined for Formula **I** (with the exception that R^1 is not $C(=O)NR^aR^b$), with 2-chloroacetaldehyde in the presence of a base; or

(c) for a compound of Formula **I** wherein R^1 is $hetAr^1$, $hetAr^2$, $hetAr^3$, Ar^1 or Ar^2, and R^2 is hydrogen, coupling a corresponding compound having the formula **V** or a protected derivative thereof



V

where R^2 is hydrogen, R^3, R^4, R^5, R^6, R^7, X^1 and X^2 are as defined for Formula **I** and L^2 is a leaving atom, with a compound having the formula **VIA** or **VIB**




R^1-Sn(alkyl)$_3$

VIA **VIB**

wherein R^1 is as defined for Formula I, R^x and R^y are H or (1-6C)alkyl, or R^x and R^y together with the atoms to which they are connected form a 5-6 membered ring optionally substituted with 1-4 substituents selected from (1-3C alkyl), wherein said coupling takes


place in the presence of a palladium catalyst and base and optionally in the presence of a ligand; or

(d) for compounds of Formula **I** wherein R^2 is hydrogen, R^4 is H or (1-6C)alkyl and R^5 is H, (1-6C)alkyl, -CH_2CN, (3-6C)cycloalkyl, $hetCyc^e$, Ar^a or $hetAr^d$, coupling a corresponding compound having the formula **VII**




VII

where R^2 is hydrogen, and R^1, R^3, X^1 and X^2 are as defined for Formula **I**, with a corresponding acrylonitrile reagent having the formula




where R^7 is as defined for Formula **I**, R^4 is H or (1-6C)alkyl and R^5 is H, (1-6C)alkyl, -CH_2CN, (3-6C)cycloalkyl, $hetCyc^e$, Ar^a or $hetAr^d$, in the presence of a base; or

(e) for a compound of Formula **I** wherein R^2 is hydrogen, and R^4 and R^5 form a 4-membered oxacyclic ring, a 5-6 membered carbocyclic ring, or an unsubstituted 4 membered azacyclic ring, coupling a corresponding compound having the formula **VII**




VII


where R^2 is hydrogen, and R^1, R^3, X^1 and X^2 are as defined for Formula **I**, with a compound having the formula **VIII-a**, **VIII-b**, or **VIII-c**, respectively



VIII-a




VIII-b



VIII-c

in the presence of a base; or


(f) for a compound of Formula **I** wherein R^4 and R^5 form a 4 or 6 membered azacyclic ring substituted with (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, benzyl, $-CH_2$(3-6C cycloalkyl) or $-CH_2$hetCyc^f, coupling a corresponding compound having the formula **IX**



IX


wherein m and n are each 1, or m and n are each 2, and R^1, R^2, R^3, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with a corresponding compound having the formula L^3-R^{10}, where L^3 is a leaving group or atom and R^{10} is (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, benzyl, $-CH_2$(3-6C cycloalkyl) or $-CH_2$hetCyc^f, in the presence of a base; or

(g) for a compound of Formula **I** wherein R^4 and R^5 form a 4 or 6 membered azacyclic ring substituted with (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, benzyl, $-CH_2$(3-6C cycloalkyl) or $-CH_2$hetCyc^f, coupling a corresponding compound having the formula **IX**




IX

wherein m and n are each 1, or m and n are each 2, and R^1, R^2, R^3, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with a corresponding aldehyde having the formula



where R^{11} is (1-5C)alkyl, fluoro(1-5C)alkyl, difluoro(1-5C)alkyl, trifluoro(1-5C)alkyl, tetrafluoro(1-5C)alkyl, pentafluoro(1-5C)alkyl, (3C)alkynyl, cyano(1-3C)alkyl, phenyl, -(3-6C cycloalkyl) or -hetCyc^f, in the presence of a base and a reducing agent; or

(h) for a compound of Formula **I** wherein R^4 and R^5 form a 4 or 6 membered azacyclic ring substituted with cyclopropyl or oxetanyl, coupling a compound having the formula **IX**




IX

wherein m and n are each 1, or m and n are each 2, and R^1, R^2, R^3, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with a corresponding ketone having the formula

 or ,

respectively, or an acetal derivative thereof, in the presence of a base and a reducing agent; or


(i) for a compound of Formula **I** wherein R^4 and R^5 form a 4 or 6 membered azacyclic ring substituted with -C(=O)(1-6Calkyl) or -C(=O)(CR'R")CF_3, coupling a corresponding compound having the formula **IX**



IX

wherein m and n are each 1, or m and n are each 2, and R^1, R^2, R^3, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with a corresponding compound having the formula $R^{12}CO_2H$ or a corresponding anhydride thereof, where R^{12} is -(1-6Calkyl) or -(CR'R")CF_3, in the presence of a base and optionally in the presence of a coupling reagent; or


(j) for a compound of Formula **I** wherein R^4 and R^5 form a 4 or 6 membered azacyclic ring substituted with SO_2CF_3, reacting a compound having the formula **IX**



IX

wherein m and n are each 1, or m and n are each 2, and R^1, R^2, R^3, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with triflic anhydride in the presence of a base; or


(k) for a compound of Formula **I** wherein R^4 and R^5 form a 4 or 6 membered azacyclic ring substituted with SO_2R^c where R^c is as defined for Formula **I**, coupling a corresponding compound having the formula **IX**



IX

wherein m and n are 1, or m and n are 2, and R^1, R^2, R^3, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with a corresponding compound having the formula $Cl\text{-}SO_2R^c$ in the presence of a base; or


(l) for a compound of Formula **I** wherein R^1 is $C(=O)NR^aR^b$, coupling a corresponding compound having the formula **X**



X

wherein R^2, R^3, R^4, R^5, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with a corresponding compound having the formula HNR^aR^b in the presence of a base and a coupling agent; or


(m) for a compound of Formula **I** wherein R^2 is Cl, reacting a corresponding compound of Formula **XI**



XI

wherein R^2 is hydrogen, and R^1, R^3, R^4, R^5, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with 1-chloropyrrolidine-2,5-dione; or


(n) for a compound of Formula **I** wherein R^2 is CN, reacting a corresponding compound of Formula **XI**



XI

wherein R^2 is hydrogen, and R^1, R^3, R^4, R^5, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with 1-iodopyrrolidinine-2,5-dione followed by treatment of the resulting 3-iodo-substituted derivative of **XI** with CuCN; or


(o) for a compound of Formula **I** wherein R^4 is hydrogen and R^5 is CH_2CN, reacting a corresponding compound having the formula **XII**



XII

wherein R^1, R^2, R^3, X^1 and X^2 are as defined for Formula I, with a dehydrating agent; or


(p) for a compound of Formula I wherein R^2 is F, reacting a corresponding compound of Formula XI



XI

wherein R^2 is hydrogen, and R^1, R^3, R^4, R^5, R^6, R^7, X^1 and X^2 are as defined for Formula I, with an electrophilic fluorinating agent; or


(q) for a compound of Formula I wherein R^2 is F, reacting a corresponding compound of Formula XIII



XIII

with an alkyl lithium or alkyl magnesium halide reagent, followed by treatment with an electrophilic fluorinating agent; or

(r) for a compound of Formula I wherein R^2 is F, reacting a corresponding compound of Formula IV




IV

with 2-chloro-2-fluoroacetaldehyde or 2-bromo-2-fluoroacetaldehyde; and

optionally removing any protecting groups and optionally preparing a salt or solvate thereof.

CLAIMS

1. A compound of the general Formula I



I

and stereoisomers and pharmaceutically acceptable salts and solvates thereof, wherein:

X^1 is N or CR^{3a} and X^2 is N or CR^{3b};

R^{3a} and R^{3b} are independently H, (1-6C alkyl), CF_3, F, Cl, CN, or (3-6C)cycloalkyl;

R^1 is $hetAr^1$, $hetAr^2$, $hetAr^3$, Ar^1, Ar^2, $C(=O)NR^aR^b$, (3-6C)cycloalkyl, or N-(1-3C alkyl)pyridinonyl;

$hetAr^1$ is a 5 membered heteroaryl ring having 1-3 ring heteroatoms independently selected from N, O and S and optionally substituted with one or more substituents independently selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, (1-4C alkoxy)(1-6C)alkyl, trimethylsilyl(1-4C alkoxy)(1-6C)alkyl, (3-6C)cycloalkyl, a 4-6 membered oxacyclic ring, $hetCyc^a$(1-2C)alkyl, $hetAr^a$(1-2C)alkyl and (1-4C alkylsulfonyl)(1-6C alkyl);

$hetCyc^a$ is a 6 membered heterocycle having 1-2 ring heteroatoms independently selected from N and O and is optionally substituted with (1-6C)alkyl;

$hetAr^a$ is a 6 membered heteroaryl having 1-2 ring nitrogen atoms;

$hetAr^2$ is a 9-membered bicyclic partially unsaturated or fully unsaturated heterocyclic ring having 3 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

$hetAr^3$ is a 6 membered heteroaryl having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl, $hetCyc^b$ and (1-6C)alkoxy;

$hetCyc^b$ is a 6-membered heterocycle having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

Ar^1 is phenyl substituted with a substituent selected from $hetCyc^c$, $hetCyc^d$, $hetAr^b$, trifluoro(1-6C)alkyl and (1-6C)alkoxy;

$hetCyc^c$ is a 6 membered heterocycle having 1-2 ring heteroatoms independently selected from N and O and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

$hetCyc^d$ is an 8-membered bridged heterocyclic ring having 1-2 ring heteroatoms independently selected from N and O;

$hetAr^b$ is a 5-membered heteroaryl ring having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

Ar^2 is a benzo ring fused to a 5-6 membered azacyclic ring and is optionally substituted with one or more substituents independently selected from (1-6C)alkyl;

R^a is H;

R^b is (1-6C)alkyl, (3-6C)cycloalkyl or $hetAr^c$;

$hetAr^c$ is a 6-membered heteroaryl having 1-2 ring N atoms;

R^2 is hydrogen, halogen, (1-4C)alkyl, CF_3, CN, (3-4C)cycloalkyl, azetidinyl or oxetanyl;

R^3 is hydrogen, (1-6C)alkyl, CF_3, F, Cl, CN or (3-6C)cycloalkyl;

R^4 is H or (1-6C)alkyl, and

R^5 is H, (1-6C)alkyl, $-CH_2CN$, (3-6C)cycloalkyl (optionally substituted by one or more halogens), $hetCyc^e$, Ar^a or $hetAr^d$,

or R^4 and R^5 together with the carbon atom to which they are attached form a 4-6 membered azacyclic ring optionally substituted with a substituent selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, benzyl, $-CH_2$(3-6C cycloalkyl), $-CH_2hetCyc^f$, -C(=O)O(1-6Calkyl), -C(=O)(1-6Calkyl), $-C(=O)(CR'R'')CF_3$, $hetAr^e$, (3-6C)cycloalkyl, a 4-6 membered oxacyclic ring and $-SO_2R^c$,

or R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered oxacyclic ring,

or R^4 and R^5 together with the carbon atom to which they are attached form a 3-6 membered carbocyclic ring optionally substituted with (1-6C)alkyl,

or R^4 and R^5 together with the carbon atom to which they are attached form a 7-9 membered bicyclic spiro carbocycle,

or R^4 and R^5 together with the carbon atom to which they are attached form a 7-9 membered bicyclic spiro heterocycle having a ring heteroatom selected from O and N, wherein said ring nitrogen atom when present is optionally substituted with a substituent selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl and $-SO_2R^c$;

$hetCyc^e$ is a 5-6-membered heterocycle having a ring N atom and substituted with a substituents selected from C(=O)(1-6C)alkyl;

Ar^a is phenyl optionally substituted with one or more substituents independently selected from halogen, CF_3, (1-6C)alkyl and (1-6C)alkoxy;

$hetAr^d$ is a 6-membered heteroaryl having 1-2 ring nitrogen atoms and optionally substituted with one or more substituents independently selected from halogen, (1-6C)alkoxy, (1-6C)alkyl and CF_3;

$hetCyc^f$ is a 6-membered oxacyclic ring;

R' and R" are independently hydrogen or methyl, or

R' and R" together with the carbon atom to which they are attached form a cyclopropylidine ring;

$hetAr^e$ is a 6-membered heteroaryl ring having 1-2 ring nitrogen atoms;

R^c is (1-6C)alkyl, fluoro(1-3C)alkyl, difluoro(1-3C)alkyl trifluoro(1-3C)alkyl, tetrafluoro(1-3C)alkyl, pentafluro(1-3C)alkyl, (3-6C)cycloalkyl (optionally substituted with (1-6C)alkyl), or phenyl (optionally substituted with one or more groups independently selected from (1-6C alkyl), CF_3, CF_3O- and halogen);

R^6 is hydrogen or methyl; and

R^7 is hydrogen or (1-6C)alkyl.

2. A compound according to claim 1, wherein R^1 is $hetAr^1$ or $hetAr^2$.

3. A compound according to claim 1, wherein R^1 is $hetAr^1$.

4. A compound according to claim 1, wherein $hetAr^1$ is pyrazolyl, thiazolyl, oxazolyl, thiadiazolyl, imidazolyl, pyrrolyl or thiophenyl optionally substituted with one or more substituents independently selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, (1-4C alkoxy)(1-6C)alkyl, trimethylsilyl(1-4C alkoxy)(1-6C)alkyl, (3-6C)cycloalkyl, a 4-6 membered oxacyclic ring, $hetCyc^a$(1-2C)alkyl and $hetAr^a$(1-2C)alkyl.

5. A compound according to claim 1, wherein $hetAr^1$ is pyrazol-4-yl, thiazol-5-yl, imidazol-1-yl or 1,3,4-thiadiazol-2-yl optionally substituted with one or more substituents independently selected from methyl, ethyl, isopropyl, isobutyl, 2,2,2-trifluoroethyl, (2-isopropoxy)ethyl, trimethylsilylethoxymethyl, cyclobutyl, oxetanyl, 4-tetrahydro-2H-pyranyl, (4-methylpiperazinyl)ethyl and pyrid-3-ylmethyl.

6. A compound according to claim 1, wherein $hetAr^1$ is pyrazol-4-yl optionally substituted with a substituent selected from methyl, ethyl, isopropyl, isobutyl, 2,2,2-trifluoroethyl, (2-isopropoxy)ethyl, trimethylsilylethoxymethyl, cyclobutyl, oxetanyl, 4-tetrahydro-2H-pyranyl, (4-methylpiperazinyl)ethyl and pyrid-3-ylmethyl.

7. A compound according to claim 1, wherein R^1 is $hetAr^2$.

8. A compound according to claim 1, wherein R^1 is $hetAr^3$.

9. A compound according to claim 1, wherein R^1 is selected from Ar^1 and Ar^2.

10. A compound according to claim 1, wherein R^1 is $C(=O)NR^aR^b$.

11. A compound according to claim 1, wherein R^4 is H or (1-6C)alkyl, and R^5 is H, (1-6C)alkyl, $-CH_2CN$, (3-6C)cycloalkyl, $hetCyc^e$, Ar^a or $hetAr^d$.

12. A compound according to claim 1, wherein R^4 is H or (1-6C)alkyl, and R^5 is H, methyl, t-butyl, 2,2-dimethylpropyl, cyanomethyl, cyclopropyl, cyclobutyl, cyclopentyl, 1-acetylpiperidin-4-yl, phenyl, trifluoromethylphenyl, chlorophenyl, pyridyl, methoxypyridyl or bromopyridyl.

13. A compound according to claim 1, wherein R^4 is H or (1-6C)alkyl, and R^5 is cyclopropyl, cyclobutyl or cyclopentyl.

14. A compound according to claim 1, wherein R^4 is H.

15. A compound according to claim 1, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered azacyclic ring optionally substituted with a substituent selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, benzyl, -CH_2(3-6C cycloalkyl), -CH_2hetCyc[f], -C(=O)O(1-6Calkyl), -C(=O)(1-6Calkyl), -C(=O)(CR'R")CF_3, hetAr[e], (3-6C)cycloalkyl, a 4-6 membered oxacyclic ring and -SO_2R^c.

16. A compound according to claim 1, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered azacyclic ring optionally substituted with a substituent selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, -CH_2(3-6C cycloalkyl), -CH_2-hetCyc[f], (3-6C)cycloalkyl and -SO_2R^c.

17. A compound according to claim 1, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered azacyclic ring optionally substituted with a substituent selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl and pentafluoro(1-6C)alkyl.

18. A compound according to claim 1, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered azacyclic ring substituted with -C(=O)O(1-6Calkyl), -C(=O)(1-6Calkyl), -C(=O)(CR'R")CF_3.

19. A compound according to claim 1, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered azacyclic ring substituted with hetAr[e].

20. A compound according to claim 1, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered azacyclic ring substituted with -SO_2R^c.

21. A compound according to claim 1, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 6-membered azacyclic ring substituted with a substituent selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, benzyl, -CH_2(3-6C cycloalkyl), -CH_2hetCyc[f], -C(=O)O(1-6Calkyl), -C(=O)(1-6Calkyl), -C(=O)(CR'R")CF_3, hetAr[e], (3-6C)cycloalkyl, a 4-6 membered oxacyclic ring and -SO_2R^c.

22. A compound of claim 1, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 5 membered azacyclic ring optionally substituted with a substituent selected from (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-

6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, benzyl, -CH_2(3-6C cycloalkyl), -CH_2hetCyc[f], -C(=O)O(1-6Calkyl), -C(=O)(1-6Calkyl), -C(=O)(CR'R")CF_3, hetAr[e], (3-6C)cycloalkyl, a 4-6 membered oxacyclic ring and -SO_2R^c.

23. A compound according to claim 1, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 4-membered oxacyclic ring.

24. A compound according to claim 1, wherein R^4 and R^5 together with the carbon atom to which they are attached form a 3-6 membered carbocyclic ring.

25. A compound according to claim 1, wherein R^7 is hydrogen.

26. A compound according to claim 1, wherein R^2 is H.

27. A compound according to claim 1, wherein R^3 is hydrogen.

28. A compound according to claim 1, wherein X^1 is N and X^2 is CR^{3b}.

29. A compound according claim 1, wherein X^1 is CR^{3a} and X^2 is N.

30. A compound according to claim 1, wherein X^1 is CR^{3a} and X^2 is CR^{3b}.


31. A compound according to claim 1, wherein R^{3a} is H.

32. A compound according to claim 1, wherein R^{3b} is H.

33. A pharmaceutical composition, which comprises a compound of Formula **I** as defined in claim 1 or a pharmaceutically acceptable salt or solvate thereof, and a pharmaceutically acceptable diluent or carrier.


34. A process for the preparation of a compound of claim 1, which comprises:

(a) coupling a corresponding compound having the formula **II** or a protected derivative thereof



II


where L^1 is a leaving atom and R^1 and R^2 are as defined for Formula **I**, with a corresponding compound having the formula **III**:



III

where R^3, R^4, R^5, R^6, R^7, X^1 and X^2 are as defined for Formula **I** and R^x and R^y are H or (1-6C)alkyl, or R^x and R^y together with the atoms to which they are connected form a 5-6 membered ring optionally substituted with 1-4 substituents selected from (1-3C alkyl), wherein said coupling takes place in the presence of a palladium catalyst and base and optionally in the presence of a ligand; or


(b) for compounds of Formula **I** wherein R^2 is hydrogen, cyclizing a corresponding compound having the formula **IV** or a protected derivative thereof



IV


where R^1, R^3, R^4, R^5, R^6, R^7, X^1 and X^2 are as defined for Formula **I** (with the exception that R^1 is not $C(=O)NR^aR^b$), with 2-chloroacetaldehyde in the presence of a base; or

(c) for a compound of Formula **I** wherein R^1 is $hetAr^1$, $hetAr^2$, $hetAr^3$, Ar^1 or Ar^2, and R^2 is hydrogen, coupling a corresponding compound having the formula **V** or a protected derivative thereof



V

where R^2 is hydrogen, R^3, R^4, R^5, R^6, R^7, X^1 and X^2 are as defined for Formula **I** and L^2 is a leaving atom, with a compound having the formula **VIA** or **VIB**




VIA

R^1-Sn(alkyl)$_3$

VIB


wherein R^1 is as defined for Formula **I**, R^x and R^y are H or (1-6C)alkyl, or R^x and R^y together with the atoms to which they are connected form a 5-6 membered ring optionally substituted with 1-4 substituents selected from (1-3C alkyl), wherein said coupling takes place in the presence of a palladium catalyst and base and optionally in the presence of a ligand; or

(d) for compounds of Formula **I** wherein R^2 is hydrogen, R^4 is H or (1-6C)alkyl and R^5 is H, (1-6C)alkyl, -CH_2CN, (3-6C)cycloalkyl, hetCyc[e], Ar[a] or hetAr[d], coupling a corresponding compound having the formula **VII**




VII

where R^2 is hydrogen, and R^1, R^3, X^1 and X^2 are as defined for Formula **I**, with a corresponding acrylonitrile reagent having the formula




where R^7 is as defined for Formula **I**, R^4 is H or (1-6C)alkyl and R^5 is H, (1-6C)alkyl, -CH_2CN, (3-6C)cycloalkyl, hetCyc[e], Ar[a] or hetAr[d], in the presence of a base; or

(e) for a compound of Formula **I** wherein R^2 is hydrogen, and R^4 and R^5 form a 4-membered oxacyclic ring, a 5-6 membered carbocyclic ring, or an unsubstituted 4 membered azacyclic ring, coupling a corresponding compound having the formula **VII**




VII


where R^2 is hydrogen, and R^1, R^3, X^1 and X^2 are as defined for Formula **I**, with a compound having the formula **VIII-a**, **VIII-b**, or **VIII-c**, respectively



VIII-a




VIII-b



VIII-c

in the presence of a base; or


(f) for a compound of Formula **I** wherein R^4 and R^5 form a 4 or 6 membered azacyclic ring substituted with (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, benzyl, -CH_2(3-6C cycloalkyl) or -CH_2hetCyc[f], coupling a corresponding compound having the formula **IX**



IX


wherein m and n are each 1, or m and n are each 2, and R^1, R^2, R^3, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with a corresponding compound having the formula L^3-R^{10}, where L^3 is a leaving group or atom and R^{10} is (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, benzyl, -CH_2(3-6C cycloalkyl) or -CH_2hetCyc^f, in the presence of a base; or

(g) for a compound of Formula **I** wherein R^4 and R^5 form a 4 or 6 membered azacyclic ring substituted with (1-6C)alkyl, fluoro(1-6C)alkyl, difluoro(1-6C)alkyl, trifluoro(1-6C)alkyl, tetrafluoro(1-6C)alkyl, pentafluoro(1-6C)alkyl, (3-4C)alkynyl, cyano(1-4C)alkyl, benzyl, -CH_2(3-6C cycloalkyl) or -CH_2hetCyc^f, coupling a corresponding compound having the formula **IX**




IX

wherein m and n are each 1, or m and n are each 2, and R^1, R^2, R^3, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with a corresponding aldehyde having the formula





where R^{11} is (1-5C)alkyl, fluoro(1-5C)alkyl, difluoro(1-5C)alkyl, trifluoro(1-5C)alkyl, tetrafluoro(1-5C)alkyl, pentafluoro(1-5C)alkyl, (3C)alkynyl, cyano(1-3C)alkyl, phenyl, -(3-6C cycloalkyl) or -hetCyc^f, in the presence of a base and a reducing agent; or

(h) for a compound of Formula **I** wherein R^4 and R^5 form a 4 or 6 membered azacyclic ring substituted with cyclopropyl or oxetanyl, coupling a compound having the formula **IX**




IX

wherein m and n are each 1, or m and n are each 2, and R^1, R^2, R^3, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with a corresponding ketone having the formula

 or ,

respectively, or an acetal derivative thereof, in the presence of a base and a reducing agent; or


(i) for a compound of Formula **I** wherein R^4 and R^5 form a 4 or 6 membered azacyclic ring substituted with -C(=O)(1-6Calkyl) or -C(=O)(CR'R")CF_3, coupling a corresponding compound having the formula **IX**



IX

wherein m and n are each 1, or m and n are each 2, and R^1, R^2, R^3, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with a corresponding compound having the formula $R^{12}CO_2H$ or a corresponding anhydride thereof, where R^{12} is -(1-6Calkyl) or -(CR'R")CF_3, in the presence of a base and optionally in the presence of a coupling reagent; or


(j) for a compound of Formula **I** wherein R^4 and R^5 form a 4 or 6 membered azacyclic ring substituted with SO_2CF_3, reacting a compound having the formula **IX**



IX

wherein m and n are each 1, or m and n are each 2, and R^1, R^2, R^3, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with triflic anhydride in the presence of a base; or


(k) for a compound of Formula **I** wherein R^4 and R^5 form a 4 or 6 membered azacyclic ring substituted with SO_2R^c where R^c is as defined for Formula **I**, coupling a corresponding compound having the formula **IX**



IX

wherein m and n are 1, or m and n are 2, and R^1, R^2, R^3, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with a corresponding compound having the formula $Cl\text{-}SO_2R^c$ in the presence of a base; or


(l) for a compound of Formula **I** wherein R^1 is $C(=O)NR^aR^b$, coupling a corresponding compound having the formula **X**



X

wherein R^2, R^3, R^4, R^5, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with a corresponding compound having the formula HNR^aR^b in the presence of a base and a coupling agent; or


(m) for a compound of Formula **I** wherein R^2 is Cl, reacting a corresponding compound of Formula **XI**



XI

wherein R^2 is hydrogen, and R^1, R^3, R^4, R^5, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with 1-chloropyrrolidine-2,5-dione; or


(n) for a compound of Formula **I** wherein R^2 is CN, reacting a corresponding compound of Formula **XI**



XI

wherein R^2 is hydrogen, and R^1, R^3, R^4, R^5, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with 1-iodopyrrolidinine-2,5-dione followed by treatment of the resulting 3-iodo-substituted derivative of **XI** with CuCN; or


(o) for a compound of Formula **I** wherein R^4 is hydrogen and R^5 is CH_2CN, reacting a corresponding compound having the formula **XII**



XII

wherein R^1, R^2, R^3, X^1 and X^2 are as defined for Formula **I**, with a dehydrating agent; or


(p) for a compound of Formula **I** wherein R^2 is F, reacting a corresponding compound of Formula **XI**



XI

wherein R^2 is hydrogen, and R^1, R^3, R^4, R^5, R^6, R^7, X^1 and X^2 are as defined for Formula **I**, with an electrophilic fluorinating agent; or


(q) for a compound of Formula **I** wherein R^2 is F, reacting a corresponding compound of Formula **XIII**



XIII

with an alkyl lithium or alkyl magnesium halide reagent, followed by treatment with an electrophilic fluorinating agent; or

(r) for a compound of Formula **I** wherein R^2 is F, reacting a corresponding compound of Formula **IV**



IV

with 2-chloro-2-fluoroacetaldehyde or 2-bromo-2-fluoroacetaldehyde; and

optionally removing any protecting groups and optionally preparing a salt or solvate thereof.

35. A compound of claim 1, selected from:

3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)pentanedinitrile;

3-Cyclopropyl-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

Enantiomer 1 of 3-cyclopropyl-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

Enantiomer 2 of 3-cyclopropyl-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)pentanedinitrile;

3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-3-(pyridin-2-yl)propanenitrile;

3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-3-(pyridin-4-yl)propanenitrile;

3-(5-methoxypyridin-3-yl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-(5-bromopyridin-3-yl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-3-phenylpropanenitrile;

3-(2-chlorophenyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-(3-chlorophenyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-(4-chlorophenyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-3-(3-(trifluoromethyl)phenyl)propanenitrile;

3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-3-phenylbutanenitrile;

3-cyclopentyl-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

4,4-dimethyl-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)pentanenitrile;

3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-cyclobutyl-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

tert-butyl 4-(cyanomethyl)-4-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)piperidine-1-carboxylate;

2-(1-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)cyclohexyl)acetonitrile;

2-(1-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)cyclopentyl)acetonitrile;

2-(3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)oxetan-3-yl)acetonitrile;

3-(4-(3-chloro-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-3-cyclopropylpropanenitrile;

5-(1-(2-cyano-1-cyclopropylethyl)-1H-pyrazol-4-yl)-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidine-3-carbonitrile;

3-(1-acetylpiperidin-4-yl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

2-(1-methyl-4-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)piperidin-4-yl)acetonitrile;

2-(1-ethyl-4-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)piperidin-4-yl)acetonitrile;

2-(4-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-propylpiperidin-4-yl)acetonitrile;

2-(4-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)piperidin-4-yl)acetonitrile;

3-cyclopropyl-3-(4-(7-(1-((2-(trimethylsilyl)ethoxy)methyl)-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-(4-(7-(1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-3-cyclopropylpropanenitrile;

3-Cyclopropyl-3-(4-(7-(1-isopropyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-cyclopropyl-3-(4-(7-(1-(pyridin-3-ylmethyl)-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-cyclopropyl-3-(4-(7-(1-(tetrahydro-2H-pyran-4-yl)-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-cyclopropyl-3-(4-(7-(1-isobutyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-Cyclopropyl-3-(4-(7-(1-(oxetan-3-yl)-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-cyclopropyl-3-(4-(7-(1-(2,2,2-trifluoroethyl)-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-cyclopropyl-3-(4-(7-(1-ethyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-cyclopropyl-3-(4-(7-(1-(2-isopropoxyethyl)-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-(4-(7-(1-cyclobutyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-3-cyclopropylpropanenitrile;

3-cyclopropyl-3-(4-(7-(oxazol-5-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-cyclopropyl-3-(4-(7-(1-(2-(4-methylpiperazin-1-yl)ethyl)-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-Cyclopropyl-3-(4-(7-(5-methyl-1,3,4-thiadiazol-2-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-Cyclopropyl-3-(4-(7-(4-methyl-1H-imidazol-1-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-Cyclopropyl-3-(4-(7-(thiazol-5-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-cyclopropyl-3-(4-(7-(2-methylthiazol-5-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-Cyclopropyl-3-(4-(7-(6-methylpyridin-3-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-cyclopropyl-3-(4-(7-(2-methylpyridin-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-cyclopropyl-3-(4-(7-(6-(4-methylpiperazin-1-yl)pyridin-3-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-Cyclopropyl-3-(4-(7-(1,2,3,4-tetrahydroisoquinolin-6-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-Cyclopropyl-3-(4-(7-(2-methyl-1,2,3,4-tetrahydroisoquinolin-6-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-Cyclopropyl-3-(4-(7-(1,2,3,4-tetrahydroisoquinolin-7-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-Cyclopropyl-3-(4-(7-(2-methyl-1,2,3,4-tetrahydroisoquinolin-7-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-Cyclopropyl-3-(4-(7-(5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-3-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-cyclopropyl-3-(4-(7-(7-methyl-5,6,7,8-tetrahydroimidazo[1,2-a]pyrazin-3-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-(4-(7-(4-(8-Oxa-3-azabicyclo[3.2.1]octan-3-yl)phenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-3-cyclopropylpropanenitrile;

3-Cyclopropyl-3-(4-(7-(4-(4-methylpiperazin-1-yl)phenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

Tert-butyl 3-(cyanomethyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate;

2-(3-(4-(7-(1-Methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(1-Acetyl-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-Methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(3,3,3-trifluoropropanoyl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-Methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(1-(trifluoromethyl)cyclopropanecarbonyl)azetidin-3-yl)acetonitrile;

2-(1-Cyclopropyl-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-Methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(oxetan-3-yl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-Methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(pyrimidin-2-yl)azetidin-3-yl)acetonitrile;

2-(1-(2,2-dDifluoroethyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-Methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,3,3,3-pentafluoropropyl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl)acetonitrile;

2-(1-ethyl-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2,2'-(3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidine-1,3-diyl)diacetonitrile;

2-(1-(3-fluoropropyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(1-(but-2-ynyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(prop-2-ynyl)azetidin-3-yl)acetonitrile;

2-(1-(2-fluoroethyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

3-(3-(cyanomethyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-1-yl)propanenitrile;

2-(1-(1,3-difluoropropan-2-yl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,3,3-tetrafluoropropyl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-propylazetidin-3-yl)acetonitrile;

2-(1-isopropyl-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(1-methyl-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(1-(cyclopropylmethyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(1-isobutyl-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(3,3,3-trifluoropropyl)azetidin-3-yl)acetonitrile;

2-(1-(cyclobutylmethyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(1-benzyl-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-((tetrahydro-2H-pyran-4-yl)methyl)azetidin-3-yl)acetonitrile;

2-(3-(4-(3-Chloro-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl)acetonitrile;

2-(1-(Isopropylsulfonyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(methylsulfonyl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(propylsulfonyl)azetidin-3-yl)acetonitrile;

2-(1-(cyclohexylsulfonyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(1-(cyclopropylsulfonyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(trifluoromethylsulfonyl)azetidin-3-yl)acetonitrile;

2-(1-(ethylsulfonyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(3,3,3-trifluoropropylsulfonyl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(phenylsulfonyl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-Isopropyl-1-H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-Isopropyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(trifluoromethylsulfonyl)azetidine-3-yl)acetonitrile;

2-(3-(4-(7-(2-Methylthiazol-5-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-Cyclobutyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-Ethyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-(Oxetan-3-yl)-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl)acetonitrile;

3-(3-methyl-4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-(5-methyl-4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

2-(3-(3-methyl-4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl)acetonitrile;

3-Cyclopropyl-3-(3-methyl-4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-Cyclopentyl-3-(4-(7-(4-(1-methylpiperidin-4-yl)phenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

Enantiomer 1 of 3-cyclopentyl-3-(4-(7-(4-(1-methylpiperidin-4-yl)phenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

Enantiomer 2 of 3-cyclopentyl-3-(4-(7-(4-(1-methylpiperidin-4-yl)phenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-Cyclopentyl-3-(4-(7-(4-morpholinophenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

Enantiomer 1 of 3-cyclopentyl-3-(4-(7-(4-morpholinophenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

Enantiomer 2 of 3-cyclopentyl-3-(4-(7-(4-morpholinophenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-methyl-3-(4-(7-(4-morpholinophenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)butanenitrile;

3-cyclopropyl-3-(4-(7-(4-morpholinophenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-(4-(7-(4-morpholinophenyl)imidazo [1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)butanenitrile;

2-methyl-3-(4-(7-(4-morpholinophenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-(4-(7-(4-morpholinophenyl) imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

3-Cyclopentyl-3-(3-methyl-4-(7-(4-morpholinophenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

N-tert-butyl-5-(1-(2-cyano-1-cyclopropylethyl)-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidine-7-carboxamide;

5-(1-(2-Cyano-1-cyclopropylethyl)-1H-pyrazol-4-yl)-N-cyclohexylimidazo[1,2-c]pyrimidine-7-carboxamide;

5-(1-(2-Cyano-1-cyclopropylethyl)-1H-pyrazol-4-yl)-N-cyclobutylimidazo[1,2-c]pyrimidine-7-carboxamide;

5-(1-(2-cyano-1-cyclopropylethyl)-1H-pyrazol-4-yl)-N-(pyridin-2-yl)imidazo[1,2-c]pyrimidine-7-carboxamide;

3-Cyclopropyl-3-(3-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrrol-1-yl)propanenitrile;

2-(3-(3-(7-(1-Methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrrol-1-yl)azetidin-3-yl)acetonitrile;

2-(3-(3-(7-(1-Methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrrol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl)acetonitrile;

Tert-butyl 3-(cyanomethyl)-3-(3-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidine-1-carboxylate;

2-(3-(3-(7-(1-Methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(3-(3-(7-(1-Methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl)acetonitrile;

3-Cyclopropyl-3-(3-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

2-(3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(trifluoromethylsulfonyl)pyrrolidin-3-yl)acetonitrile;

2-(1-acetyl-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)pyrrolidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)pyrrolidin-3-yl)acetonitrile;

2-(1-(cyclopropylsulfonyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(4-(4-methylpiperazin-1-yl)phenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(4-(4-methylpiperazin-1-yl)phenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(trifluoromethylsulfonyl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(2-methylthiazol-5-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(trifluoromethylsulfonyl)azetidin-3-yl)acetonitrile;

2-(1-(cyclopropylsulfonyl)-3-(4-(7-(2-methylthiazol-5-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(1-(cyclopropylsulfonyl)-3-(4-(7-(2-methoxypyrimidin-5-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(2-methoxypyrimidin-5-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(trifluoromethylsulfonyl)azetidin-3-yl)acetonitrile;

2-(3-(3-(7-(1-(2-(methylsulfonyl)ethyl)-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl)acetonitrile;

2-(3-(3-(7-(1-methyl-2-oxo-1,2-dihydropyridin-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl)acetonitrile;

2-(3-(3-(7-(1-methyl-6-oxo-1,6-dihydropyridin-3-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(4-(trifluoromethyl)phenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(trifluoromethylsulfonyl)azetidin-3-yl)acetonitrile;

3-(2,2-difluorocyclopropyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

(S)-3-((S)-2,2-difluorocyclopropyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

R)-3-((S)-2,2-difluorocyclopropyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

(S)-3-((R)-2,2-difluorocyclopropyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

(R)-3-((R)-2,2-difluorocyclopropyl)-3-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

2-(6-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-2-oxaspiro[3.3]heptan-6-yl)acetonitrile;

2-(3-(4-(7-cyclopropylimidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl)acetonitrile;

2-(2-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-7-oxaspiro[3.5]nonan-2-yl)acetonitrile;

3-cyclopropyl-3-(4-(3-fluoro-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)propanenitrile;

2-(3-(4-(3-chloro-7-(1-(oxetan-3-yl)-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,2-trifluoroethyl)azetidin-3-yl)acetonitrile;

2-(3-(4-(3-fluoro-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-((trifluoromethyl)sulfonyl)azetidin-3-yl)acetonitrile;

2-(3-(4-(3-chloro-7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-((trifluoromethyl)sulfonyl)azetidin-3-yl)acetonitrile;

2-(1-(2,2-difluoroethyl)-3-(4-(7-(1-(oxetan-3-yl)-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(1-(oxetan-3-yl)-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(2,2,3,3,3-pentafluoropropyl)azetidin-3-yl)acetonitrile;

2-(3-(4-(7-(4-methoxyphenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)-1-(trifluoromethylsulfonyl)azetidin-3-yl)acetonitrile;

2-(1-(cyclopropylsulfonyl)-3-(4-(7-(4-methoxyphenyl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)azetidin-3-yl)acetonitrile;

2-(2-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)spiro[3.3]heptan-2-yl)acetonitrile;

2-(2-(4-(7-(1-methyl-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)spiro[3.4]octan-2-yl)acetonitrile;

2-(2-(4-(7-(1-(oxetan-3-yl)-1H-pyrazol-4-yl)imidazo[1,2-c]pyrimidin-5-yl)-1H-pyrazol-1-yl)spiro[3.3]heptan-2-yl)acetonitrile;

or a pharmaceutically acceptable salt or solvate thereof.